B. Winningham

Learn More
PURPOSE To determine adverse reaction rates in a tertiary care clinical setting after adoption of gadoteridol as the institutional routine magnetic resonance (MR) imaging contrast agent. MATERIALS AND METHODS With institutional review board approval, informed consent waiver, and HIPAA compliance, a prospective observational study of 28 078 patients who(More)
  • 1